MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Mibefradil dihydrochloride

CAS No. : 116666-63-8

產(chǎn)品活性：Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca²⁺ channels (IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively).

研究領(lǐng)域：Membrane Transporter/Ion Channel  |  Neuronal Signaling

作用靶點：Calcium Channel

In Vitro: Mibefradil dihydrochloride inhibits reversibly the T- and L-type currents with IC₅₀ values of 2.7 and 18.6 μM, respectively. The inhibition of the L-type current is voltage-dependent, whereas that of the T-type current is not. Ro 40-5967 blocks T-type current already at a holding potential of -100 mV At a higher concentration (20 µM), Mibefradil reduces the amplitude of excitatory junction potentials (by 37±10 %), slows the rate of repolarisation (by 44±16 %) and causes a significant membrane potential depolarisation (from ?83±1 mV to ?71±5 mV). At a higher Mibefradil concentration (20 µM) there is significant membrane potential depolarisation and a slowing of repolarisation. These actions of Mibefradil are consistent with K⁺ channel inhibition, which has been shown to occur in human myoblasts and other cells.

In Vivo: The hearing thresholds of the 24-26 week old C57BL/6J mice differ following the 4-week treatment period. The hearing threshold at 24 kHz is significantly decreased in the Mibefradil-treated and benidipine-treated groups compared with the saline-treated group (P<0.05). Compared with the saline-treated group, rats receiving Mibefradil or NSC 64013 show significant lower Ca_V3.2 expression in the spinal cord and DRG.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Neuroprotective Compound Library  |  Rare Diseases Drug Library  |  Calcium Channel Blocker Library  |  FDA-Approved Anticancer Drug Library  |  Off-patent Drug Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Benidipine hydrochloride  |  Isotachysterol 3  |  IAA65  |  Ranolazine-d₈ (dihydrochloride)  |  Diltiazem hydrochloride  |  Palmitoylglycine  |  Lercanidipine-¹³C,d₃-1 (hydrochloride)  |  Efonidipine hydrochloride monoethanolate  |  L-Ascorbic acid sodium salt  |  Taurolithocholic acid-d₄ (sodium)  |  Nilvadipine  |  N-type calcium channel blocker-1  |  Lercanidipine  |  SQ-31765  |  CP-060  |  ISX-9  |  Nisoldipine-d₆  |  Catharanthine  |  Ginsenoside Rd  |  Manidipine dihydrochloride  |  Ziconotide  |  MMK1  |  Ranolazine-d₅  |  Isradipine  |  L-Ascorbic acid-¹³C₆  |  AE0047 Hydrochloride  |  Brompheniramine maleate  |  FPL64176

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。